Three Biotechs Before the Move: Why FDA Catalysts Can Double a Price Overnight

The video opens with one question: what really fires a biotech price? The answer hides in company size. At giants like Eli Lilly and AbbVie a patent that expires does not shake the stock on a single readout, because the portfolio is broad; at small clinical names such as Kodiak and Capricor there is no commercial sale yet, so without an approval there is no revenue. That is why the small-cap investor watches the calendar, while the large-cap watcher tracks pipeline renewal rhythm. Host and analyst Chris Markoch lay that split first, then explain why the daily top-movers list is so often crowded with the same sector jumping more than 100 percent.

The Patent Cliff and Why a Pipeline Must Stay Full

The patent cliff — when protection ends and generic competition quickly erodes sales — is the background lesson. Large drug makers must feed new candidates every year or the shelf empties, so the research pipeline should never run dry. Think of an apartment building that lines up the next lease before the current one ends: a large owner can tolerate one empty flat, but a small guesthouse that misses one room may have to turn the sign off. For small biotech, Phase 3 is the key that opens that one door; if it succeeds the chest fills, if it fails value drains fast. The mechanism explains the three names in the video.

How can a price double in a day? Three levers line up. One, the share trades in the 10 to 15 dollar band and institutional ownership is light, so retail appetite fills the room. Two, short exposure is high — the talk cites 42 percent for Capricor, the latest FINRA filing prints 33.63 — so good news can force a short squeeze with unusual force. Three, volume travels fast on a thin tape. For example, a single upbeat headline from a 690-patient eye study can unbalance a board where few institutions and many individuals are waiting. Together the three show why volatility in biotech is structural, not accidental.

Kodiak Sciences: A 690-Patient Eye Study With Two Shots

Kodiak Sciences (KOD) is the most mature name on the table. A run of about 250 percent in the past year lifted market value to 2.06 billion dollars and into mid-cap territory, yet it still has no commercial drug and the focus stays on the retina. The target is wet age-related macular degeneration (wet AMD — vision loss from leaky abnormal vessels behind the retina), a leading cause of blindness treated today with anti-VEGF standard care. At the time of recording the share sits near 33 dollars, after trading above 40 a month earlier, with a 52-week range of 9.22 to 47.84, a 50-day mean of 39.43 and a 200-day mean of 37.07; eight brokers carry a mean target of 48.14 dollars, institutional ownership stands at 89.06 percent with Baker Bros, BlackRock and Janus Henderson adding.

The catalyst is named Daybreak. Under one roof it is really two Phase 3 studies: candidates tarcocimab tedromer, also called Zenkuda (KSI-301), and KSI-501, each tested in treatment-naive wet AMD against aflibercept. The design gives two paths from one readout, with about 690 patients split across arms. In the first six months the Zenkuda arm dosed every eight weeks while the comparator dosed every four; in the second half identical retreatment criteria applied and nearly half of Zenkuda patients needed no extra treatment while vision and anatomy matched the comparator at one year. In plain words, an antibody construct that quiets leaky vessels is paired with a biopolymer scaffold to promise fewer injections.

The calendar explains the recent pressure. The company said enrollment was complete on August 10; the MarketBeat tracker visible during taping showed data in the second quarter of 2027, while the second-quarter 2026 financial bulletin points to September 2026 for the one-year primary endpoint. Whichever proves current, the message is the same: no near-term readout, only waiting. That explains a 20 percent slide in the past month after an earlier anticipation rally. The analyst take is straightforward: the pullback can be a window, a drift toward 30 dollars as June support would be a calmer entry, and building a position gradually makes sense if the thesis is trusted, knowing that FDA binary risk stays at every entry.

Capricor and Invivyd: Two Edges of Risk

Capricor Therapeutics (CAPR) reads as more fragile. The focus is cell and exosome-based therapy for rare disease; the lead is deramiocel for Duchenne muscular dystrophy (DMD — a progressive rare genetic condition that wastes muscle) where the primary endpoint of the pivotal HOPE-3 study is upper limb function. A Biologics License Application (BLA — the FDA dossier that allows a biologic to be marketed) is under review and the PDUFA goal day (PDUFA — the fee-based deadline the FDA commits to for a decision) moved from August 22 to November 22, 2026. The reason is not a rejection but a major amendment: Capricor added 24-month open-label extension data from HOPE-3 and extra robustness work for a refined upper-limb indication, and the agency extended by three months to review.

Price and ownership mirror the delay. CAPR is down about 70 percent year-to-date, gave back a December spike in late July and rebounded about 27.8 percent in the past month; the August 14 filing shows short interest at 33.63 percent at 6.65 dollars after 3.85 on July 31. Institutional ownership is only about 21 percent, so retail does the heavy lifting, and twelve analysts carry a mean target of 30.25 dollars implying more than 250 percent upside, but the label stays speculative. For those who bought near 30 to 35 dollars the loss is deep; for a new entry patience before the November decision and a small position discipline are needed, as a single statement can launch the price either way.

Invivyd (IVVD) is the table's surprising exception: not purely clinical, already revenue-generating, yet micro at 247 million dollars and 84 cents, squarely a penny name. The marketed product is Pemgarda (pemivibart — a long-acting monoclonal antibody for pre-exposure prophylaxis in immunocompromised people) and the candidate VYD2311 has a DECLARATION Phase 3 with a readout near the end of the third quarter. The firm posted more than 14 million dollars last quarter on August 13, up about 20 percent year over year, but with post-pandemic enthusiasm lower the cash-burn question stays alive. The paradox is this: despite only 14 million in revenue, eight analysts cover the name, institutional ownership is about 70 percent and short is 11 percent and calm, with a mean target of 8 dollars implying more than 840 percent upside. The schedule is not fixed; the company says it will hold a detailed investor call when data arrive, outside the earnings call, with expectations pointing to late 2026 or early 2027.

The closing section reminds how money runs out in biotech. Phases are long, launch needs capital too, and there is no dividend to pay you for waiting. Fourteen million helps relieve pressure but the chest that carries the trial and, later, the launch must stay funded with fresh rounds if needed. The host therefore sets two practical rules: keep the speculative slice small and build gradually; on the other side hold steadier buy-and-hold names for balance, with a separate seven-stock list and a free MarketBeat FDA tracker on offer. The split tries to keep the window open while keeping the floor solid.